Nanoparticles for use for treating a neuronal disorder
The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject when the nanoparticle or nanoparticles' aggregate is exposed to an electric field, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ε ijk equal to or above 200, and an insulator material with a dielectric constant ε ijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.
1. A method for normalizing impaired synchronization of oscillations within and/or between neuronal networks within and/or between distinct regions of the brain in a patient in need thereof, wherein the method comprises i) administering a composition to the subject, the composition comprising nanoparticles and/or nanoparticles aggregates and a pharmaceutically acceptable support, and the nanoparticle or nanoparticles aggregate material being selected from a conductor material selected from a metal having a standard reduction potential E° above 0.2 selected from Pd, Pt and Au, and an intrinsic semiconductor material with a band gap Eg below 3.0 eV selected from an element from group IVA of the Mendeleev's periodic table, a mixed composition of elements from groups III and V of the Mendeleev's periodic table, and a mixed composition of elements from group II and VI of the Mendeleev periodic table, and ii) exposing the subject to an electric field.
2. The method according to claim 1 , wherein the composition comprises gold nanoparticles coated with a biocompatible hydrophilic agent having a neutral surface charge, or coated with a biocompatible agent having a negative surface charge.
3. The method according to claim 1 , wherein the composition comprises silicon nanoparticles coated with a biocompatible hydrophilic agent having a neutral surface charge or silicon nanoparticles coated with a biocompatible agent having a negative surface charge.
4. The method according to claim 1 , wherein the patient is suffering from a neurological disease or at least one symptom thereof selected from Parkinson disease, Alzheimer disease, autism spectrum disorder, a depression disorder, schizophrenia, dementia, or bipolar disorder.
5. The method according to claim 1 , wherein the composition comprises at least two distinct nanoparticles and/or nanoparticles aggregates, each nanoparticle or nanoparticles aggregate comprising a distinct material selected from a conductor material selected from a metal having a standard reduction potential E° above 0.2 selected from Pd, Pt and Au, and an intrinsic semiconductor material with a band gap Eg below 3.0 eV, selected from an element from group IVA of the Mendeleev's periodic table, a mixed composition of elements from groups III and V of the Mendeleev's periodic table and a mixed composition of elements from group II and VI of the Mendeleev periodic table.